Cardiovascular outcomes of sodium glucose cotransporter‐2 inhibitors in patients with type 2 diabetes
Diabetes Obesity and Metabolism2018Vol. 21(1), pp. 28–36
Citations Over TimeTop 10% of 2018 papers
Abstract
Using population-based data, incident use of SGLT-2 inhibitors was associated with a decreased incidence of CVD compared to use of sulfonylureas and DPP-4 inhibitors. These findings were consistent between dapagliflozin and canagliflozin, suggesting that CVD reduction is a class effect for SGLT2 inhibitors. In addition, SGLT2 inhibitors portended lower risk of hospitalization because of heart failure (vs sulfonylureas and DPP-4 inhibitors) and lower risk of lower extremity amputation (vs sulfonylureas).
Related Papers
- → Differentiating the Sodium‐Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling(2020)39 cited
- → Comparison of Canagliflozin, Dapagliflozin and Empagliflozin Added to Heart Failure Treatment in Decompensated Heart Failure Patients With Type 2 Diabetes Mellitus(2019)31 cited
- → A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin(2015)20 cited
- → Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates(2017)4 cited
- Sodium Glucose Co-Transporter-2 Inhibitors, Type 2 Diabetes mellitus, Canagliflozin, Dapagliflozin, Empagliflozin, Extra Glycaemic Effects, Adverse effects(2021)